Estudios originales
Published on 17 de marzo de 2025 | http://doi.org/10.5867/medwave.2025.02.2962
COVID-19 as a risk factor for the development of pulmonary fibrosis in a referral hospital in Lima, Peru
| Age – years | 72 (62 to 79) | 72 (62 to 79) | 72 (62 to 79) | 0,8732 |
| Female | 341 (58.2) | 178 (60.8) | 163 (55.6) | 0.2093 |
| Comorbidities4 | ||||
| Arterial hypertension | 210 (11.9) | 106 (12.1) | 104 (11.8) | 0.8833 |
| Cancer of any site | 172 (9.8) | (3.4) | 142 (16) | |
| DM 2 | 75 (4.3) | 29 (3.3) | 46 (5.2) | |
| Hypothyroidism | 49 (2.8) | 33 (3.8) | 16 (1.8) | |
| CKD | 45 (2.6) | 29 (3.3) | 16 (1.8) | 0.0493 |
| In patients with a history of hospitalization for COVID-19 | ||||
| Days of hospitalization | 18.5 (9.25 to 48.75) | 22 (13 to 53.5) | 14.5 (7 to 31.5) | 0.4882 |
| Hospitalization in EsSalud (versus other centers) | 29 (72.5) | 12 (54.5) | 17 (94.4) | |
| ICU admission | 12 (30) | 7 (31.8) | 5 (27.8) | 0.7813 |
CKD, chronic kidney disease.DM 2, type 2 diabetes mellitus. EsSalud, Social Health Insurance healthcare network. HTN, hypertension. ICU, intensive care unit. PF, pulmonary fibrosis.
Notes: 1Continuous data are shown as median and interquartile range and categorical data as number (%). 2Mann-Whitney U test. 3Chi-square test. 4The percentages of comorbidities per group were calculated based on the total number of comorbidities reported. A patient could report more than one comorbidity.
Notes: Values in bold were statistically significant.
Source: Table designed by the authors based on the results.